US30063P1057
© BusinessWire
11.12.2025
EXAS
LISTED
NASDAQ
Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS
News Preview
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first clinical study results from its Oncodetect® molecular residual disease (MRD) test in breast cancer. Findings from the NSABP B-59 substudy, conducted in collaboration with the NSABP Foundation and the German Breast Group (GBG)...
Themefolio
Profiler
Peergroup
© BusinessWire
24.11.2025
EXAS
LISTED
NASDAQ
Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts across its Precision Oncology portfolio at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place from December 9-12 in San Antonio, Texas.
The data to be presented builds upon Exact Sciences’ long-standing commi...
Themefolio
Profiler
Peergroup
© BusinessWire
22.11.2025
EXAS
LISTED
NASDAQ
Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS
News Preview
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Exact Sciences Corporation (NasdaqCM: EXAS) to Abbott Laboratories (NYSE: ABT). Under the terms of the proposed transaction, shareholders of Exact Sciences will receive $105.00 in cash for ea...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
20.11.2025
EXAS
LISTED
NASDAQ
EXAS Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Exact Sciences Corporation is Fair to Shareholders
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Exact Sciences Corporation (NASDAQ: EXAS) to Abbott for $105.00 per common share in cash is fair to Exact Sciences shareholders.
Halper Sadeh encourages Exact Sciences shareholders to click here to learn more about their legal rights and options or contact Daniel...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
10.11.2025
EXAS
LISTED
NASDAQ
Exact Sciences Announces Expiration of the HSR Waiting Period for Exclusive License to Freenome’s Blood-Based Colorectal Cancer Screening Tests
News Preview
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) for its previously announced license agreement with Freenome. Under the agreement, the Company acquired exclusive rights in the U...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2025
EXAS
LISTED
NASDAQ
Exact Sciences Announces Breakthrough Results from Landmark Study Demonstrating Superior Early Detection of Liver Cancer with Blood-Based Surveillance Test
News Preview
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced pivotal clinical validation results from the ALTUS study (NCT: 05064553). The prospective, head-to-head trial demonstrated that the company’s Oncoguard® Liver blood test delivers superior early-stage and overall sensitivity for hepatoc...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
EXAS
LISTED
NASDAQ
Exact Sciences to Participate in November Investor Conference
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
Jefferies London Healthcare Conference, London
Fireside chat on Tuesday, November 18, 2025 at 7:30 a.m. ET (12:30...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
EXAS
LISTED
NASDAQ
Exact Sciences Announces Third Quarter 2025 Results
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $851 million for the third quarter ended September 30, 2025, compared to $709 million for the same period of 2024.
“Exact Sciences continues to advance our mission to prevent cancer and detect it...
Themefolio
Profiler
Peergroup
© BusinessWire
27.10.2025
EXAS
LISTED
NASDAQ
Exact Sciences Presents New Findings at ACG 2025 Demonstrating How the Cologuard Test Helps Improve Adherence and Close Screening Gaps
News Preview
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced new data being presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place October 24–29, 2025, at the Phoenix Convention Center in Phoenix, Arizona. The company’s research showcases leadership i...
Themefolio
Profiler
Peergroup
© BusinessWire
08.10.2025
EXAS
LISTED
NASDAQ
Exact Sciences Schedules Third Quarter 2025 Earnings Call
News Preview
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2025 financial results after the close of the U.S. financial markets on November 3, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. E...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
EXAS
LISTED
NASDAQ
New Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest Colonoscopies
News Preview
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests today announced the publication of “Comparing Benefit-to-Burden Ratios of Endorsed and Emerging Colorectal Cancer Screening Strategies” in the Journal of the National Cancer Institute.1 The modeling study found that Cologuard Plus™, a triennial next-ge...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
EXAS
LISTED
NASDAQ
Horror Icon Matthew Lillard and Exact Sciences Help Adults 45+ Conquer Fear and Get Screened for Colon Cancer with the Cologuard® Test
News Preview
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, is teaming up with actor and horror icon Matthew Lillard to encourage people 45 and older to get screened for colorectal cancer—the nation’s second leading cause of cancer-related death.1
This press release features multimedia. View the full release...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
10.09.2025
EXAS
LISTED
NASDAQ
Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) blood test that is now available as a laboratory-developed test (LDT) in the United States. Cancerguard is the first MCED test commercially available that analyzes multiple biomarker cl...
Themefolio
Profiler
Peergroup
© BusinessWire
19.08.2025
EXAS
LISTED
NASDAQ
Exact Sciences to Participate in September Investor Conferences
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.
Wells Fargo Healthcare Conference, Boston
Fireside chat on Wednesday, September 3, 2025 at 1:30 p.m. ET
Baird...
Themefolio
Profiler
Peergroup
© BusinessWire
31.07.2025
EXAS
LISTED
NASDAQ
Exact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard Plus™ Test
News Preview
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc. to enhance access to colorectal cancer (CRC) screening.
Through the partnership, the Cologuard Plus™ test will be available as an in-network service for eligible Humana Medicare Advantage memb...
Themefolio
Profiler
Peergroup
© BusinessWire
14.07.2025
EXAS
LISTED
NASDAQ
Exact Sciences Schedules Second Quarter 2025 Earnings Call
News Preview
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2025 financial results after the close of the U.S. financial markets on August 6, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET...
Themefolio
Profiler
Peergroup
© BusinessWire
09.07.2025
EXAS
LISTED
NASDAQ
Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) test has received Medicare coverage through the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services Program (MolDX) for serial use in patients with sta...
Themefolio
Profiler
Peergroup
© BusinessWire
28.05.2025
EXAS
LISTED
NASDAQ
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap
News Preview
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced new data to be presented from the Beta-CORRECT clinical validation study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Results from Beta-CORRECT, a subset of the GALAXY cohort, validate the performance of its...
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
EXAS
LISTED
NASDAQ
Exact Sciences to Participate in June Investor Conference
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
William Blair 45th Annual Growth Stock Conference, Chicago
Presentation on Tuesday, June 3, 2025 at 9:40 a.m. ET...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
EXAS
LISTED
NASDAQ
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
News Preview
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30–June 3, 2025, in Chicago, Ill. Presentations include new data on the Oncodetect™ molecular residual disease (MRD...
Themefolio
Profiler
Peergroup
© BusinessWire
12.05.2025
EXAS
LISTED
NASDAQ
Exact Sciences Earns 2025 Great Place To Work® Certification™
News Preview
Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as a 2025 Great Place To Work® for the seventh consecutive year in the U.S., and for the first time in the U.K., Japan, Canada, France, Italy, Poland, and Germany.
The recognition is based on a confidential survey...
Themefolio
Profiler
Peergroup
© BusinessWire
02.05.2025
EXAS
LISTED
NASDAQ
Exact Sciences to Participate in May Investor Conference
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
BofA Securities Health Care Conference, Las Vegas
Fireside chat on Wednesday, May 14, 2025 at 1:40 p.m. ET (10:40 a...
Themefolio
Profiler
Peergroup
© BusinessWire
01.05.2025
EXAS
LISTED
NASDAQ
Exact Sciences Announces First-Quarter 2025 Results
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $707 million for the first quarter ended March 31, 2025, compared to $638 million for the same period of 2024.
“Our strong first quarter results pave the way for 2025 to mark our most transformati...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
EXAS
LISTED
NASDAQ
Exact Sciences to Highlight Cologuard® Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025
News Preview
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present 15 abstracts during Digestive Disease Week (DDW) 2025, taking place May 3-6, 2025, in San Diego, California. The abstracts demonstrate high adherence and strong predicted preference for the Cologuard® test alon...
Themefolio
Profiler
Peergroup
© BusinessWire
22.04.2025
EXAS
LISTED
NASDAQ
Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of Oncodetect™—a new test designed to detect molecular residual disease (MRD) across multiple solid tumors. The Oncodetect test provides patients and their healthcare providers with the insights needed to make more informed...
Themefolio
Profiler
Peergroup
© BusinessWire
14.04.2025
EXAS
LISTED
NASDAQ
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the publication of a comprehensive review in JAMA Oncology that strengthens the evidence supporting the Oncotype DX Breast Recurrence Score test. The peer-reviewed article titled, “Genomic Assays for Breast Cancer in Diverse Population...
Themefolio
Profiler
Peergroup
© BusinessWire
01.04.2025
EXAS
LISTED
NASDAQ
Exact Sciences Schedules First Quarter 2025 Earnings Call
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2025 financial results after the close of the U.S. financial markets on May 1, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to...
Themefolio
Profiler
Peergroup
© BusinessWire
31.03.2025
EXAS
LISTED
NASDAQ
Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of Cologuard Plus™, the most accurate noninvasive colorectal cancer screening (CRC) test reported in studies to date.* FDA-approved for average-risk patients 45+ and covered by Medicare, the Cologuard Plus test detects 95% o...
Themefolio
Profiler
Peergroup
© BusinessWire
12.03.2025
EXAS
LISTED
NASDAQ
Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner
News Preview
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2025 Gallup Exceptional Workplace Award (GEWA), marking the second year in a row the company has received this prestigious recognition. This award recognizes the most engaged workplace cultures in the world.
Gallup...
Themefolio
Profiler
Peergroup
© BusinessWire
24.02.2025
EXAS
LISTED
NASDAQ
Exact Sciences to Participate in March Investor Conferences
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.
TD Cowen Health Care Conference, Boston
Fireside chat on Monday, March 3, 2025 at 10:30 a.m. ET
Raymond James...
Themefolio
Profiler
Peergroup
© BusinessWire
19.02.2025
EXAS
LISTED
NASDAQ
Exact Sciences Announces Fourth Quarter 2024 Results
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $713 million for the fourth quarter of 2024 and $2.76 billion for the full year of 2024, both ended December 31, 2024.
“The Exact Sciences team is off to a good start in 2025, building on the mome...
Themefolio
Profiler
Peergroup
© BusinessWire
03.02.2025
EXAS
LISTED
NASDAQ
Exact Sciences Schedules Fourth Quarter 2024 Earnings Call
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2024 financial results after the close of the U.S. financial markets on February 19, 2025. Following the release, company management will host a webcast and conference call at 5 p.m....
Themefolio
Profiler
Peergroup
© BusinessWire
21.01.2025
EXAS
LISTED
NASDAQ
New Evidence Validates Oncodetect's™ Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, shared clinical validation data for its OncodetectTM MRD test at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI.) Results from Alpha-CORRECT, a study with one of the longest MRD surveillance monitoring perio...
Themefolio
Profiler
Peergroup
© BusinessWire
21.01.2025
EXAS
LISTED
NASDAQ
Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 11 abstracts at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) meeting January 23-25, 2025, in San Francisco.
“The data we are presenting at ASCO GI underscore Exact Sciences’ leadership in advanc...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
EXAS
LISTED
NASDAQ
Exact Sciences Announces Preliminary Fourth Quarter 2024 Results
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company expects to report revenue of $713 million for the fourth quarter ended December 31, 2024.
"The Exact Sciences team delivered strong results to finish 2024, setting us up for sustained growth and profitability in the...
Themefolio
Profiler
Peergroup
© BusinessWire
02.01.2025
EXAS
LISTED
NASDAQ
Exact Sciences to Participate in J.P. Morgan Healthcare Conference
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
J.P. Morgan Healthcare Conference, San Francisco
Presentation followed by Q&A on Monday, January 13, 2025 at 1...
Themefolio
Profiler
Peergroup
© BusinessWire
26.11.2024
EXAS
LISTED
NASDAQ
Exact Sciences to Participate in December Investor Conferences
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.
Citi Global Healthcare Conference, Miami
Fireside chat on Tuesday, December 3, 2024 at 8:45 a.m. ET
Evercore...
Themefolio
Profiler
Peergroup
© BusinessWire
25.11.2024
EXAS
LISTED
NASDAQ
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the 2024 annual San Antonio Breast Cancer Symposium® (SABCS®) from December 10-13 in San Antonio, Texas.
“Exact Sciences is committed to improving breast canc...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2024
EXAS
LISTED
NASDAQ
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
News Preview
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection (MCED) test. The results of a study evaluating a new multi-biomarker class approach showed improved sensitivity for early-stage and...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2024
EXAS
LISTED
NASDAQ
Exact Sciences Announces Third-Quarter 2024 Results
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $709 million for the third quarter ended September 30, 2024, compared to $628 million for the same period of 2023.
“The Exact Sciences’ team is helping eradicate cancer while strengthening our pla...
Themefolio
Profiler
Peergroup
© BusinessWire
01.11.2024
EXAS
LISTED
NASDAQ
Exact Sciences to Participate in November Investor Conference
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
Jefferies London Healthcare Conference, London
Fireside chat on Tuesday, November 19, 2024 at 6:00 a.m. ET
The we...
Themefolio
Profiler
Peergroup
© BusinessWire
27.10.2024
EXAS
LISTED
NASDAQ
Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement
News Preview
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present modeling data evaluating the simulated benefit and burden of established CRC screening strategies, including the Cologuard Plus™ test during the American College of Gastroenterology (ACG) Annual Meeting. ACG ta...
Themefolio
Profiler
Peergroup
© BusinessWire
08.10.2024
EXAS
LISTED
NASDAQ
Exact Sciences Schedules Third Quarter 2024 Earnings Call
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2024 financial results after the close of the U.S. financial markets on November 5, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. E...
Themefolio
Profiler
Peergroup
© BusinessWire
04.10.2024
EXAS
LISTED
NASDAQ
FDA Approves Exact Sciences’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening
News Preview
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the U.S. Food and Drug Administration (FDA) approved the Cologuard Plus™ test, the company’s next generation multitarget stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and older who are average risk for colo...
Themefolio
Profiler
Peergroup
© BusinessWire
16.09.2024
EXAS
LISTED
NASDAQ
Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024
News Preview
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal cancer (CRC) screening test. Results show sensitivities of 88.3% for CRC and 31.2% for advanced precancerous lesions at specificity of 90.1% for negative samples confirmed by colonoscopy....
Themefolio
Profiler
Peergroup
© BusinessWire
28.08.2024
EXAS
LISTED
NASDAQ
Exact Sciences to Participate in September Investor Conferences
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.
Wells Fargo Healthcare Conference, Boston
Fireside chat on Wednesday, September 4, 2024 at 3:45 p.m. ET
Bair...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2024
EXAS
LISTED
NASDAQ
Exact Sciences Announces First Patient Enrolled in its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence Study
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the first patient has joined its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence (RWE) study at Baylor Scott & White, the primary study site and largest not-for-profit health system in Texas. The multi-...
Themefolio
Profiler
Peergroup
© BusinessWire
15.08.2024
EXAS
LISTED
NASDAQ
New Modeling Data Show the Cologuard® Test Has Detected More Than 623,000 Cancers and Precancers Over Past Decade, Saving U.S. Health Care System $22 Billion
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, shared new modeling data today describing the projected impact of the Cologuard test on patients, health care professionals, and the U.S. health care system since its FDA approval 10 years ago.
The data assessed the far-reaching benefits of the firs...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
